{
    "nctId": "NCT02646735",
    "briefTitle": "Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients",
    "officialTitle": "A Randomized, Open Label, Multi-Centre Study to Compare the Efficacy and Tolerability of Fulvestrant 500mg With Exemestane for Postmenopausal Advanced Breast Cancer Patients",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 148,
    "primaryOutcomeMeasure": "PFS",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Signed informed consent document on file;\n* Age over 60 years;\n* Age \\< 60 years and amenorrheic for 12 or more months in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression and FSH and oestradiol level in the postmenopausal range;\n* Patients with metastatic or locally advanced disease not amenable to therapy with Curative intent\n* ER + and/or PgR +;\n* Duration of adjuvant non-aromatase inhibitors treatment should be at least 2 years or more;\n* WHO performance status 0, 1 or 2;\n* Patients with life expectancy of more than 3 months.\n\nExclusion Criteria:\n\n* Presence of life-threatening metastatic visceral disease;\n* Previous systemic chemotherapy for advanced breast cancer;\n* Received systemic endocrine therapy for advanced disease;\n* Extensive radiation therapy within the last 4 weeks ;\n* Platelets \\< 100\\*109 / L,Total bilirubin no less than 1.5ULRR, ALT or AST no less than 2.5ULRR if no demonstrable liver metastases or no less than 5ULRR in presence of liver metastases;\n* Severe renal impairment, bleeding diathesis, long-term anticoagulant therapy;\n* History of hypersensitivity to active or inactive excipients of fulvestrant, Exemestane and/or castor oil.",
    "sex": "ALL",
    "minimumAge": "N/A",
    "stdAges": "CHILD, ADULT, OLDER_ADULT"
}